Sheena Sahota, MD
Hematology & Oncology · Austin, TXNPI 1225266596
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $625 of the $821 with a category attached, or 76.2%. It is spread thinly across 20 manufacturers, the largest accounting for just 22.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $270 and has fallen 86.4% since, to $37 in 2025. That places this record below the midpoint for hematology & oncology clinicians in TX, where the typical reported total is $3,204.
Across 38 payments — averaging $21.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$181
- Merck$86
- AbbVie$66
- Lilly USA, LLC$58
- Pharmacyclics LLC, An Abbvie Company$55
- Bristol Myers Squibb$39
- plus $336 from 14 others
Across 23 payments — averaging $8731.52 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Exelixis Inc.$201K
What the payments were for
- Food & beverage$62576%
- Education$19624%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 6 | $181 |
| Merck | 5 | $86 |
| AbbVie | 3 | $66 |
| Lilly USA, LLC | 3 | $58 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $55 |
| Bristol Myers Squibb | 2 | $39 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $37 |
| Johnson & Johnson | 2 | $34 |
| Jazz Pharmaceuticals Inc. | 1 | $34 |
| E.r. Squibb & Sons, L.L.C. | 2 | $33 |
| Tempus AI, Inc | 1 | $29 |
| Ipsen Biopharmaceuticals, Inc | 1 | $29 |
| Sanofi-aventis U.S. LLC | 1 | $23 |
| Novartis | 1 | $23 |
| Array Biopharma Inc | 1 | $22 |
| Incyte Corporation | 1 | $19 |
| Blueprint Medicines Corporation | 1 | $15 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $15 |
| AstraZeneca | 1 | $13 |
| Boehringer Ingelheim | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INLYTA$124
How this compares
$821 in reported general payments places this provider in the 25th percentile of 838 hematology & oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Austin
- Michael LattanziAustin$222K
- Devesh PandyaHouston$1.8M
- Elias JabbourHouston$1.3M
- Asad DeanFort Worth$1.1M
- Habte YimerTyler$934K
- Edward PearsonDallas$900K
- Naval DaverHouston$853K
- Christopher MaiselDallas$713K
- Clifton LaymanEl Paso$645K
- Jorge Cortes-FrancoHouston$627K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.